Sharda Cropchem plans 10-15% price hike, FY27 view

What changed and why it matters

Sharda Cropchem is preparing to implement a 10-15% price increase to counter a sharp rise in procurement costs for key raw materials, most of which are sourced from China. The company’s stated objective is to pass a part of the cost inflation to customers and protect operating margins.

The development is relevant for investors because pricing power is often the key swing factor in agrochemicals when input costs move quickly. It also comes at a time when management commentary points to improving global demand, normalising channel inventories, and gradual recovery in sector pricing.

China-linked procurement costs behind the planned hikes

The company is facing a significant increase in procurement costs for raw materials, with the majority sourced from China. The proposed 10-15% hike is positioned as a direct response to this pressure.

While the article does not specify which molecules or geographies will see the first round of hikes, the intention is clear: higher input costs are being pushed through the price chain. For Sharda Cropchem, maintaining margin stability matters because its operating model depends on scaling volumes across geographies while managing procurement and registration-led growth.

Management’s FY27 guidance at a glance

Management guidance provided in the article highlights a targeted FY27 growth profile built on volumes and broadly stable margins. The key numbers reiterated include:

• FY27 revenue expected to grow 10-15%.
• Gross margin expected around 35% (with a stated band of plus or minus a few percentage points).
• EBITDA margin expected at 18-20%.
• Effective tax rate expected at 18-20% for FY27 and FY28.
• FY27 volume growth projected around 15%.
• Non-agrochemical segment expected to grow 5-10%.

Separately, one brokerage note cited management maintaining a “bullish outlook” with revenue growth guidance of 15-20% and volume growth of 15% for FY27. Investors should note that the article contains both sets of guidance references.

A strong quarter and improved profitability signals

The article describes a strong performance period with profits rising sharply and margins expanding, linking the improvement to a better global agrochemical cycle. In a Business Today TV interaction, Chairman and Managing Director RV Bubna attributed the momentum to strong global demand, limited competition, and Sharda Cropchem’s investments in product registrations.

A transcript excerpt in the article also references a 13% year-on-year uptick in quarterly sales to ₹265 crore, alongside net profit rising 57% to ₹319 crore from ₹204 crore. The same broader compilation also reports consolidated revenue from operations rising 22% year-on-year to ₹5,268 crore, and PAT more than doubling to ₹681 crore, a 124% year-on-year jump.

Because these figures appear to come from different periods and sources within the provided text, they are best read as separate performance datapoints rather than a single reconciled set.

What drove the growth: volumes, FX and mix

For FY26, the company’s growth bridge was spelled out in the article: volume growth of 13.4%, foreign exchange impact of plus 10.3%, and price and product mix impact of minus 1.8%, leading to roughly 21.9% overall growth.

The same management message also pointed to improved demand conditions, normalised distributor inventories, and gradual price recovery as key operating drivers. This context helps explain why Sharda Cropchem is now trying to manage the next variable, higher China-linked procurement costs, through pricing.

Registrations remain a key strategic lever

A recurring theme in the article is Sharda Cropchem’s investment in product registrations across geographies as a growth engine. In the cited brokerage commentary, the company was described as having 3,004 registrations and 1,076 pending applications, which together act as a regulatory barrier to entry.

Management also linked recent top-line momentum to the accelerating contribution of this expanding registration pipeline. In agrochemicals, registrations often determine the breadth of addressable markets and the timing of product launches, making this metric central to medium-term growth visibility.

Market impact: margins, pricing and customer pass-through

The immediate market relevance of the proposed 10-15% price hike is its role as a margin defence tool. If procurement costs rise sharply, a company must either accept margin compression or raise prices, and Sharda Cropchem has signalled it will attempt to pass costs through.

At the same time, the company’s FY27 guidance suggests it expects gross margins to remain around 35% and EBITDA margins at 18-20. That implies management believes pricing actions, mix, and operating leverage can offset cost headwinds to a meaningful extent, although the article does not quantify the exact magnitude of the raw material inflation.

Key numbers table

What analysts highlighted in research notes

The article also includes brokerage commentary. One report mentioned Khambatta Securities maintaining a ‘BUY’ rating with a target price of ₹1,299. Another note referenced a ‘Buy’ rating with a target price of ₹1,250 and projected revenue and EBITDA growth rates of 14% and 26% over FY25-28.

The same research commentary cited margin expansion (for example, gross margin expanding by 700 basis points year-on-year to 34.5% in one period), aided by improved demand and pricing along with stable input costs during that phase.

Conclusion

Sharda Cropchem’s planned 10-15% price hike is a direct response to higher China-linked procurement costs, with the company aiming to protect operating margins while keeping FY27 growth on track. Management guidance points to 10-15% revenue growth, gross margins around 35%, and EBITDA margins of 18-20, supported by volume growth and a large registration pipeline.

The next key checkpoints, based on the article’s guidance, will be how effectively the company executes price pass-through and whether margin bands remain consistent as procurement costs evolve through FY27.